|Bid||167.17 x 800|
|Ask||175.00 x 2200|
|Day's Range||167.63 - 170.21|
|52 Week Range||137.70 - 179.84|
|PE Ratio (TTM)||60.02|
|Earnings Date||Oct 24, 2018 - Oct 29, 2018|
|Forward Dividend & Yield||1.88 (1.13%)|
|1y Target Est||183.93|
From $8.80 on May 8, Tandem Diabetes Care’s (TNDM) stock price steadily rose to a high of $33.44 on August 3. It recovered after that to its current level of $30.75.
Dentsply Sirona (XRAY) has lowered its guidance for fiscal 2018. It now expects adjusted EPS of $2–$2.15 compared to the previous estimate of $2.55–$2.65. The decrease represents Dentsply’s expectation of a decline in revenue for the remainder of 2018, driven by higher levels of inventory destocking at its dealer partners.
Since its second-quarter earnings release on July 7, Dentsply Sirona (XRAY) stock has plummeted ~20%. In this series, we’ll explore its financial performance, how its segments are performing, its recent acquisitions, its valuation metrics, and what analysts expect in the coming months. Dentsply Sirona is a leading global manufacturer of professional dental products and technologies.
NEW YORK, Aug. 09, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ING ...
DENTSPLY (XRAY) gains from solid year-over-year international revenue growth in Q2; high impairment charges in the quarter mars results.
In its fiscal third-quarter conference call, Hologic (HOLX) narrowed the projected range of its fiscal 2018 EPS from $2.22–$2.27 to $2.24–$2.26. Considering the midpoint of the updated EPS guidance range, the company expects YoY (year-over-year) EPS growth of ~10.8% for fiscal 2018.
During its fiscal third quarter conference call, Hologic (HOLX) raised its fiscal 2018 non-GAAP revenue guidance from $3.18 billion–$3.21 billion to ~$3.21 billion–$3.22 billion. So, its YoY (year-over-year) reported revenue growth rate for fiscal 2018 is expected to be 4.8%–5.3%, higher than the previously projected range of 4.0%–4.9%.
In the fiscal third quarter, Hologic reported non-GAAP EPS of ~$0.58, which was a YoY rise of 16.0%. Hologic surpassed its revenue and EPS guidance for the fiscal third quarter. Hologic’s Diagnostics business posted a recovery compared to the fiscal second quarter, and its Surgical business has posted gradual improvement since the fiscal first quarter.
The Medical product market gains momentum owing to the recent two-year suspension of the controversial 2.3% Medical Device tax.
Integer Holdings (ITGR) gains on solid Cardio & Vascular revenues and high organic sales; a solid guidance raises optimism.
Express Scripts (ESRX) witnesses year-over-year decline in adjusted network claims in Q2, thanks to the loss of certain public sector clients.
AmerisourceBergen (ABC) registers strong growth in the Pharmaceutical Distribution segment and the World Courier business in Q3.
An upbeat 2018 guidance instills investor's optimism for athenahealth (ATHN). However, lackluster performance in the Implementation and other segment is a persistent headwind.
Microsoft • MSFT-Nasdaq Outperform • Price $104.40 on July 19 by Evercore ISI Expectations were running high into Microsoft’s fiscal fourth-quarter results, and it delivered another phenomenal quarter highlighted by strong commercial bookings (up 18% in constant-currency gains) and Azure (cloud apps) growth up 85% [all figures in constant currency]. While the commercial cloud business (up 50%, to $6.9 billion, in revenue) continues to garner much of the attention, we believe Microsoft saw strong performance across all of its business lines, with continued acceleration in LinkedIn (up 34%) and gaming (up 38%). Looking forward, the company continues to see a strong backdrop for its commercial offerings, and we expect another year of double-digit top-line growth and some modest operating leverage (despite a big jump in capital expenditures in fiscal 2018).
Varian Medical Systems (VAR) reported its fiscal Q3 2018 results on July 25. Net sales surged 12% YoY (year-over-year) from $632.8 million to $709.1 million.
Stryker (SYK) released its second-quarter results on July 24. The company’s net sales surged 10.3% from $3.01 billion in Q2 2017 to $3.3 billion in Q2 2018. Stryker’s Neurotechnology and Spine segment, which grew by 19.4%, contributed the most to Stryker’s revenue growth. Sales from its other two segments, Orthopaedics and MedSurg, grew by 7.6% and 8.9%, respectively. The increase in the company’s revenues came from higher unit volumes, partially offset by lower prices.
NEW YORK, NY / ACCESSWIRE / July 25, 2018 / U.S. markets finished moderately higher on Tuesday, fueled by strong corporate earnings as Google quarterly results topped expectations. The Dow Jones Industrial ...